After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight-loss drug Wegovy.

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US patients at a discount.

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.

Novo Nordisk is cutting prices on weight-loss drug Wegovy, a week after Eli Lilly did the same for rival Zepbound.

The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the Danish company behind Wegovy, announced Wednesday that it has lowered its monthly cost by 23%. The new price—$499 per month—takes effect immediately. It had been $650 a month.

Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket. The deal is available through the drugmaker's new NovoCare Pharmacy offering.

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of $499 takes effect immediately.

Minnesota lawmakers are renewing a push to require insurance coverage of anti-obesity drugs like Ozempic and Wegovy. Why it matters: These life-changing drugs, known as GLP-1s, are helping millions of Americans shed pounds and lower their risk of more serious conditions like heart attacks and strokes.

Novo Nordisk said it would drop prices by 25 percent for all doses of the drug, making the new monthly price about $500.

US taxpayers spent an estimated $6 billion researching, developing, and implementing new blockbuster weight-loss drugs, according to new data shared with the Lever. Yet Americans are now paying pharmaceutical giants — including one in Denmark — up to eleven times more for these medicines than patients in other countries,